Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 2
1993 10
1994 5
1995 8
1996 9
1997 15
1998 30
1999 28
2000 23
2001 68
2002 66
2003 100
2004 130
2005 129
2006 172
2007 185
2008 188
2009 163
2010 178
2011 215
2012 200
2013 208
2014 196
2015 241
2016 244
2017 265
2018 251
2019 266
2020 300
2021 336
2022 368
2023 376
2024 372
2025 446
2026 198

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,284 results

Results by year

Filters applied: . Clear all
Page 1
Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Finn RS, et al. N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303. N Engl J Med. 2016. PMID: 27959613 Free article. Clinical Trial.
Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the p …
Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo- …
Letrozole for Female Infertility.
Yang AM, Cui N, Sun YF, Hao GM. Yang AM, et al. Front Endocrinol (Lausanne). 2021 Jun 16;12:676133. doi: 10.3389/fendo.2021.676133. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34220713 Free PMC article. Review.
It has been more than 20 years since the initial clinical trial of letrozole for ovulation induction. In light of the accumulating clinical and basic evidence, the efficacy and safety of letrozole have been identified. This mini review focuses on our current knowled …
It has been more than 20 years since the initial clinical trial of letrozole for ovulation induction. In light of the accumulating cl …
Letrozole: Pharmacology, toxicity and potential therapeutic effects.
Mukherjee AG, Wanjari UR, Nagarajan D, K K V, V A, P JP, T TP, Chakraborty R, Renu K, Dey A, Vellingiri B, Gopalakrishnan AV. Mukherjee AG, et al. Life Sci. 2022 Dec 1;310:121074. doi: 10.1016/j.lfs.2022.121074. Epub 2022 Oct 13. Life Sci. 2022. PMID: 36243120 Review.
The highly active estrogen metabolism and receptor protein expression are to blame for the elevated breast cancer (BC) rate in post-menopausal women. Letrozole is a powerful endocrine medication that targets and inhibits the aromatase, often known as an aromatase inhibitor …
The highly active estrogen metabolism and receptor protein expression are to blame for the elevated breast cancer (BC) rate in post-menopaus …
Letrozole (Femara).
Gerken P. Gerken P. Clin J Oncol Nurs. 2004 Jun;8(3):314-5. doi: 10.1188/04.cjon.314-315. Clin J Oncol Nurs. 2004. PMID: 15208828 No abstract available.
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. Rugo HS, et al. Breast Cancer Res Treat. 2019 Apr;174(3):719-729. doi: 10.1007/s10549-018-05125-4. Epub 2019 Jan 10. Breast Cancer Res Treat. 2019. PMID: 30632023 Free PMC article. Clinical Trial.

RESULTS: After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). ...The improvement of PFS with palbociclib-letrozole

…
RESULTS: After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 …
Letrozole.
Dellapasqua S, Colleoni M. Dellapasqua S, et al. Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):251-9. doi: 10.1517/17425250903540246. Expert Opin Drug Metab Toxicol. 2010. PMID: 20095792 Review.
TAKE HOME MESSAGE: Letrozole is a well-tolerated and effective drug in metastatic breast cancer in postmenopausal women. ...Future developments include the combination of letrozole with new biologic agents and tailoring of treatment with gene expression profiling st …
TAKE HOME MESSAGE: Letrozole is a well-tolerated and effective drug in metastatic breast cancer in postmenopausal women. ...Future de …
Approval summary: letrozole (Femara tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
Cohen MH, Johnson JR, Justice R, Pazdur R. Cohen MH, et al. Oncologist. 2011;16(12):1762-70. doi: 10.1634/theoncologist.2011-0287. Epub 2011 Nov 16. Oncologist. 2011. PMID: 22089970 Free PMC article. Review.
Food and Drug Administration converted letrozole (Femara ; Novartis Pharmaceuticals Corporation, East Hanover, NJ) from accelerated to full approval for adjuvant and extended adjuvant (following 5 years of tamoxifen) treatment of postmenopausal women with hormone re …
Food and Drug Administration converted letrozole (Femara ; Novartis Pharmaceuticals Corporation, East Hanover, NJ) from accele …
Femara and the future: tailoring treatment and combination therapies with Femara.
Ellis M, Ma C. Ellis M, et al. Breast Cancer Res Treat. 2007;105 Suppl 1(Suppl 1):105-15. doi: 10.1007/s10549-007-9697-2. Epub 2007 Oct 3. Breast Cancer Res Treat. 2007. PMID: 17912640 Free PMC article. Review.
Far from making present therapies redundant, these new discoveries open the door to novel combination therapies that promise to provide enhanced efficacy or overcome treatment resistance. Letrozole, one of the most potent aromatase inhibitors, is the ideal candidate for co …
Far from making present therapies redundant, these new discoveries open the door to novel combination therapies that promise to provide enha …
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Franik S, et al. Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4. Cochrane Database Syst Rev. 2022. PMID: 36165742 Free PMC article.
We included five additional trials for this update that now includes a total of 41 RCTs (6522 women). The AI, letrozole, was used in all trials. Letrozole compared to SERMs with or without adjuncts followed by timed intercourse Live birth rates were higher with l …
We included five additional trials for this update that now includes a total of 41 RCTs (6522 women). The AI, letrozole, was used in …
Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial.
Al-Thuwaynee S, Swadi AAJ. Al-Thuwaynee S, et al. J Med Life. 2023 May;16(5):725-730. doi: 10.25122/jml-2023-0069. J Med Life. 2023. PMID: 37520487 Free PMC article. Clinical Trial.
Polycystic ovary syndrome (PCOS) is characterized by menstrual irregularities, high androgen levels, and ovarian cysts. Clomiphene citrate (Clomid) and letrozole have both been investigated as ovulation induction therapies for PCOS. This interventional study aimed to compa …
Polycystic ovary syndrome (PCOS) is characterized by menstrual irregularities, high androgen levels, and ovarian cysts. Clomiphene citrate ( …
5,284 results